Plasma cell P170 expression and response to treatment in multiple myeloma

Haematologica

Volumn 81, Issue 3, 1996, Pages 232-237

  Patriarca, Francesca ^a   Melli, Cristina ^a   Damiani, Daniela ^a   Michieli, Mariagrazia ^a   Michelutti, Angela ^a   Cavo, Michele ^b   Baccarani, Michele ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anthracycline; Multidrug resistance; Multiple myeloma; P170 glycoprotein

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN EXPRESSION;

ADULT; AGED; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PLASMA CELLS;

EID: 0030324322     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wolley PVIII, Tew KD. Mechanism of drug resistance in neoplastic cells. Bristol-Meyer Cancer symposia, Academic Press, 1988.
2. Beck WT. Mechanism of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II and other factors. Cancer Treat Rev 1990; 17 (suppl. A): 113-20.
3. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989; 16:156-9.
4. Holmes JA. Multidrug resistance in leukemia. Leuk Lymphomal 1990; 1:163-8.
5. Weinstein RS, Kurskak JR, Kluskens LF, Coons JS. P-glycoprotein in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990; 2:34-48.
6. Pastan I, Gottesman M. Multiple drug resistance in human cancer. N Engl J Med 1987; 316:1388-93.
7. Kyle AR. Newer approaches in the therapy of multiple myeloma. Blood 1990; 76:1678-9.
8. Alexanian R, Dinopoulos MA. Management of multiple myeloma. Semin Hematol 1995; 32:20-30.
9. Chronic Leukemia-Myeloma Task Force Committee. National Cancer Institute. Proposed guidelines for protocol studies. II plasma cell myeloma. Cancer Chemother Rep 1973; 4:145-58.
10. Durie GBM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-54.
11. Michieli M, Damiani D, Geromin A, et al. Overexpression of multidrug resistance-associated P170 glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992; 48:87-92.
12. Michelutti A, Michieli M, Damiani D, et al. Overexpression of mdr related p 170 glycoprotein in chronic myeloid leukemia. Haematologica 1994; 79:200-4.
13. Michieli MG, Raspadori D, Damiani D, Geromin A, Baccarani M. The expression of the multidrug resistance associated glycoprotein in B cell chronic lymphocytic leukaemia. Br J Haematol 1991; 77:460-5.
14. Ishikawa H, Kawano MM, Okade K, et al. Expression of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 1993; 83:68-74.
15. Riccardi A, Invernizzi R, Ucci G, et al. P170 glycoprotein in multiple myeloma and acute leukemia. Haematologica 1991; 76 (suppl.): 177-80.
16. Solary E, Bidan JM, Calvo F, et al. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and lymphoma. Leukemia 1991; 5:592-7.
17. Linsenmeyer ME, Jefferson S, Wolf M, et al. Levels of expression of the mdr1 gene and glutathion-S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992; 65:471-5.
18. Salmon SE, Grogan TM, Miller T, et al. Predicting doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989; 81:696-701.
19. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78:44-50.
20. Durie BGM, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68:203-6.
21. Dalton WS, Grogan TM, Mettzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7:415-24.
22. Epstein J, Xiao HQ, Oba KB. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989; 74:913-7.
23. Musto P, Lombardi G, Matera R, et al. The expression of the multidrug transporter p170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma. Haematologica 1991; 76:513-6.
24. Carulli G, Petrini M, Marini A, et al. P-glycoprotein expression in multiple myeloma. Haematologica 1990; 75:288-90.
25. Dalton WS, Durie BGM, Alberts DS, et al. Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein. Cancer Res 1986; 46:5125-30.
26. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81:490-5.
27. Sonneveld P, Durie BG, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet 1992; 340:255-9.
28. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994; 12:1584-91.
29. Cornelissen JJ, Sonneveld P, Shoester M, et al. MDR-1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994; 12:115-9.
30. A Southwest Oncology Group Study. A phase III randomized study of oral verapamil to reverse drug resistance in patients with refractory myeloma. Cancer 1995; 75:815-20.
31. Dalton WS, Grogan TM, Rybski JA, et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistance human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73:747-52.
32. Pilarski L, Belch AR. Circulating monoclonal B cells expressing P-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 1994; 83:724-36.
33. Carulli G, Petrini M. Multidrug resistance: focus in hematology. Haematologica 1990; 76:363-74.
34. Haber D. Multidrug resistance (mdr-1) in leukemia: is it time to test? Blood 1992; 79:295-8.